Charge-Switching Lipids Make Lipid Nanoparticles Safer for Gene Delivery

Lipid nanoparticles have become one of the most celebrated delivery vehicles in modern medicine, propelling messenger RNA vaccines to the forefront of the global response to the COVID-19 pandemic and opening a credible path toward RNA therapeutics for cancer, genetic disease, and inflammation. Yet for all their clinical success, these tiny fat-based capsules carry a persistent liability: the very chemical feature that lets them smuggle genetic cargo into cells also makes them inflammatory and, in sufficiently high doses, toxic. A new study published in Nature Nanotechnology reports a molecular redesign that could ease that trade-off. Researchers have developed charge-switching ionizable lipids, termed S-lipids, that remain neutral or mildly negative in the bloodstream but flip to a positive charge inside the acidic compartments of the cell where gene delivery actually takes place. The result, according to the authors, is a class of lipid nanoparticles that deliver nucleic acids effectively while provoking markedly less inflammation than conventional formulations.

To appreciate why this charge choreography matters, it helps to revisit how standard lipid nanoparticles work. A typical formulation combines an ionizable lipid with helper lipids, cholesterol, and polyethylene glycol-conjugated lipids, all assembled around a nucleic acid payload such as mRNA or siRNA. The ionizable lipid is engineered with an amine group whose protonation state depends on acidity: at the near-neutral pH of blood, roughly 7.4, the lipid is mostly uncharged, which keeps the particle circulations friendly and limits interactions with serum proteins and cell membranes. When the particle is taken up by a cell and lands in an endosome, whose interior becomes progressively more acidic, the amine group acquires a positive charge. This electrostatic switch lets the lipid blend with and destabilize the endosomal membrane, allowing the payload to escape into the cytoplasm where it can be translated or processed.

The problem is that cationic charge is inherently disruptive. Positively charged lipids and particles can bind avidly to negatively charged cell surfaces, destabilize plasma membranes, and trigger innate immune signaling pathways, including inflammasome activation and inflammatory cytokine release. Clinicians see the consequences as infusion reactions, fever, and dose-limiting toxicities that constrain how much therapeutic material can be administered, a particular obstacle for applications that require repeated or systemic dosing. Preclinical studies have long documented that ionizable lipids with lower pKa values and more biodegradable linkages tend to be better tolerated, but the field has continued to search for designs that decouple endosomal escape efficiency from extracellular reactivity.

The S-lipids described in the new work take that decoupling a step further. Instead of merely being less protonated at physiological pH, these lipids are designed to carry a neutral or even negative charge while circulating, so that the nanoparticle surface presents little of the cationic character associated with membrane damage and immune activation. Only when the particle encounters the strongly acidic environment inside endosomes does the chemical group undergo its switch, becoming positively charged at precisely the moment and location where membrane disruption is useful. In effect, the designers have shifted the charge transition from a gradual acid-base titration to a sharper, compartment-specific event, concentrating cationic activity where it helps and eliminating it where it harms.

According to the study, lipid nanoparticles built from these charge-switching lipids deliver nucleic acids with an efficiency comparable to that of conventional ionizable lipid formulations, despite presenting a non-cationic exterior in the extracellular environment. In cell-based assays and animal models, the S-lipid nanoparticles induced substantially reduced inflammatory responses, a difference the authors attribute to the absence of persistent positive surface charge during circulation and initial cell contact. The findings suggest that the inflammation commonly associated with lipid nanoparticle therapy is driven in large part by cationic interactions that occur before the particle ever reaches an endosome, and that these interactions can be engineered away without sacrificing the delivery mechanism that makes the technology valuable.

The implications reach across the growing portfolio of nucleic acid medicine. mRNA vaccines and therapeutics, siRNA gene silencing, CRISPR-based genome editing, and prime editing strategies all depend on lipid nanoparticles or close cousins to ferry their fragile cargo past cell membranes and endosomal traps. Each of these modalities is limited by the maximum tolerated dose of lipid. If charge-switching lipids genuinely lower toxicity while preserving potency, they could raise the ceiling on how much genetic instruction or editing machinery can be delivered in a single treatment, which in turn could improve efficacy against tumors, extend duration of protein expression, or reduce the frequency of dosing for chronic conditions. Safer lipids would also matter for patients with pre-existing inflammatory conditions, for whom even mild cytokine activation can be clinically significant.

The chemistry behind the switch reflects a broader trend in nanomedicine toward stimuli-responsive materials. Researchers have previously explored pH-sensitive polymers, acid-labile linkers, and ionizable heads with tuned pKa values, all in pursuit of the same goal: keeping a delivery vehicle inert in circulation and active inside the cell. The S-lipid approach refines this strategy at the level of the lipid headgroup itself, encoding environmental sensitivity into the molecular structure rather than relying on a detachable protecting group or a formulation additive. Such intrinsic responsiveness can be advantageous because it does not depend on a chemical reaction that competes with biological degradation, and because the behavior of the particle is determined uniformly by every lipid molecule in its shell.

There are, of course, familiar gaps between promising preclinical materials and routine clinical tools. Charge-switching lipids must demonstrate manufacturability at scale, stability during storage, predictable behavior across species, and safety profiles that satisfy regulators over repeated exposures. The acidic microenvironments of tumors and inflamed tissues, which some delivery strategies exploit, could in principle trigger premature charge switching, although the authors’ data focus on the endosomal route that dominates lipid nanoparticle uptake. Biodistribution, complement activation, and long-term accumulation of the new lipid species in liver and other organs will require the same scrutiny applied to every prior generation of ionizable lipids. Still, the conceptual advance, that toxicity can be reduced by sharpening the pH dependence of lipid charge rather than by broadly softening the lipid, gives formulation scientists a new design axis to explore alongside biodegradability, pKa tuning, and structural diversity generated by combinatorial synthesis.

The study lands at a moment when the lipid nanoparticle pipeline is expanding far beyond its vaccine origins. Companies and academic groups are advancing inhaled, implantable, and targeted formulations; conjugating antibodies and ligands to particle surfaces; and exploring delivery to cell types, such as T cells and hematopoietic stem cells, that have resisted lipid-based transfection. Every one of those programs inherits the same core constraint of the cationic switch, and any chemistry that relaxes that constraint without weakening delivery is likely to be adopted quickly. As the field matures from proving that nucleic acid delivery works to optimizing how well and how safely it works, charge-switching S-lipids offer a concrete, mechanistically grounded answer to one of the platform’s oldest criticisms: that the vehicle that saves the payload from destruction should not itself become the source of the patient’s discomfort.

For now, the result stands as an elegant demonstration that a single, well-chosen molecular property, the timing of a charge transition, can reshape the biological personality of an entire delivery platform. If subsequent studies in larger animals and human trials confirm the reduced inflammation reported here, the modest S-lipid may take its place alongside the ionizable lipids that preceded it as a quiet but consequential upgrade to the technology that carried mRNA medicine into the clinic.

The distinction between a gradual titration curve and a sharp switching threshold has practical consequences for how such particles behave in blood. Serum albumin and other abundant proteins carry their own net charges, and conventional ionizable lipid nanoparticles can acquire a protein corona whose composition influences both clearance and immune recognition. A particle surface that presents neutral or anionic character should interact with this corona differently, potentially altering which proteins adsorb and how the particle is routed through the liver and spleen. The authors’ observation that reduced inflammation tracks with the absence of persistent cationic surface charge is consistent with this picture, though the precise corona composition of S-lipid formulations remains an open question for follow-up work.

Endosomal escape itself remains one of the least efficient steps in the delivery process, with estimates suggesting that only a small fraction of internalized nucleic acid ever reaches the cytoplasm. Any headgroup chemistry that preserves membrane-disruptive activity at endosomal pH while silencing it elsewhere therefore addresses the central bottleneck rather than trading one limitation for another. The sharper pH dependence reported for S-lipids suggests that the protonation event can be concentrated within the narrow acidity range of late endosomes, where the payload must be released, rather than beginning in early endosomes or, worse, at the cell surface.

It is also worth noting that inflammation from lipid nanoparticles is not a single mechanism but a collection of overlapping pathways, including complement activation, toll-like receptor signaling, and inflammasome engagement, each with different dose thresholds and kinetics. Reducing cationic contact may dampen several of these at once, but disentangling which pathways are most sensitive to surface charge will help predict which patient populations benefit most. Such mechanistic mapping, together with head-to-head comparisons against clinically validated ionizable lipids, will determine whether the safety margin demonstrated in preclinical models translates into meaningfully higher tolerated doses in humans.

Subject of Research: Development of charge-switching ionizable lipids that reduce the toxicity and inflammatory effects of lipid nanoparticles for nucleic acid delivery.

Article Title: Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles

Article References: Liang, D., Qi, Y., Han, H., Ahmadian, N., Gao, K., Sapasap, K., Zhang, Y., Guo, S., Lawanprasert, A., Pimcharoen, S., Zhao, S., Del Buono, M. T., Xia, H., Enders, Z. O., Burgstone, B. W., Calio, A., Dankar, N., Lu, B., Qi, L. S., … Murthy, N. (2026). Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles. Nature Nanotechnology. https://doi.org/10.1038/s41565-026-02262-6

Image Credits: AI Generated

DOI: 10.1038/s41565-026-02262-6

Keywords: lipid nanoparticles, ionizable lipids, charge-switching, mRNA delivery, nucleic acid delivery, inflammation, nanotechnology, endosomal escape, drug delivery, RNA therapeutics, biocompatibility, nanomedicine